EMEA-001207-PIP02-19-M01 - paediatric investigation plan
Obinutuzumab
PIPHuman
Roche Registration GmbH
Tel. +41 616879411
E-mail: global.paediatrics@roche.com
P/0296/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for obinutuzumab (Gazyvaro), (EMEA-001207-PIP02-19-M01)